Silver Bullet Mines posts gold assays up to 41.1 g/t at Columbia/Gold Queen complex in Arizona
Bitget2026/10/08 20:07Silver Bullet Mines reported new gold assays from the Columbia/Gold Queen Complex in Arizona, including 41.14 g/t gold (1.2 opt). Sampling also returned high-grade results from a nearby stockpile, including 27.43 g/t gold and up to 312 g/t silver. A third-party lab reported Steamboat Mine samples up to 3.5 g/t gold and 41.7 g/t silver from channel chip sampling. Work is being used to target higher-grade concentrate production at its Globe, Arizona mill; third-party assays on recent concentrate are pending. Road access was built to the Columbia Mine; a new road to the Gold Queen is nearing completion to support modern hauling. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silver Bullet Mines Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610081605NEWSFILECNPR____20261008_318146_1) on October 08, 2026, and is solely responsible for the information contained therein.
- Silver Bullet Mines reported new gold assays from the Columbia/Gold Queen Complex in Arizona, including 41.14 g/t gold (1.2 opt).
- Sampling also returned high-grade results from a nearby stockpile, including 27.43 g/t gold and up to 312 g/t silver.
- A third-party lab reported Steamboat Mine samples up to 3.5 g/t gold and 41.7 g/t silver from channel chip sampling.
- Work is being used to target higher-grade concentrate production at its Globe, Arizona mill; third-party assays on recent concentrate are pending.
- Road access was built to the Columbia Mine; a new road to the Gold Queen is nearing completion to support modern hauling.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - RBC expects gradual improvement in North American and European building materials stocks in the third quarter
October 9 - RBC expects the performance of most European building material products to gradually improve quarter-on-quarter in Q3, but notes that geopolitical uncertainties in the US will continue to drive up cost inflation and increase market volatility. RBC anticipates that sales in Europe will remain sluggish due to heatwaves and rising mortgage rates, while a weak US housing market and the lack of a significant hurricane season will prompt roofing material companies to enter a destocking cycle. The firm is more optimistic about Germany’s Heidelberg Group (HEIG.DE), upgrading its rating to “outperform,” and points out that the company has handled the challenging quarter caused by extreme weather far better than its peers. Due to severe cost headwinds such as rising diesel and natural gas prices, RBC downgraded the ratings of US and French construction companies Knife River (KNF.N) and Saint-Gobain (SGOB.PA) from “outperform” to “market perform.” (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them solely for the ease of the reader. Reuters assumes no liability for any damages or losses that may arise from the use of automated translation functions.)
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
